The Peptide NewsroomPeptide research, industry and supply-chain headlines

Ascletis Files US IND for Once-Weekly Oral Quadruple Peptide Agonist in Obesity

Topic card: fda

Ascletis Pharma has submitted an IND application to the U.S. Food and Drug Administration for ASC36_37o FDC, a once-weekly oral tablet the Hong Kong company describes as a potential first-in-class combination of four obesity targets. Every efficacy and pharmacokinetic figure in the announcement comes from rats and non-human primates, and the human program has not started.

The tablet is a fixed-dose combination of two peptides: ASC36, an amylin receptor agonist, and ASC37, a triple agonist hitting GLP-1R, GIPR and GCGR. Those are the same receptor families behind semaglutide and tirzepatide, with amylin now the fashionable fourth addition across the obesity field.

The pill problem

Peptides are hard to deliver orally because the gut destroys them, which is why the drugs people actually take for obesity are mostly injections. Ascletis says ASC36_37o FDC was built on its POTENT oral delivery platform, designed to raise oral bioavailability and reduce pharmacokinetic variability by absorbing at both gastric and intestinal sites.

In non-human primates at steady state, the company reported half-lives of up to 200 hours, roughly 8.3 days, for ASC36 and up to 96 hours, 4 days, for ASC37, with oral bioavailability above 10% and at or above 9.1% respectively. Ascletis says combining the two extended ASC36's half-life from about 7 days as a single agent to about 8.3 days, and lifted its oral bioavailability from 6% to 8% alone to more than 10% in the combination.

What the rat data showed

In head-to-head diet-induced obese rat studies, the company says co-formulating the two peptides produced approximately 69% greater body weight reduction than ASC37 alone and approximately 192% greater reduction than ASC36 alone. Those are company-reported preclinical numbers against its own monotherapies, not against any marketed drug, and the percentages describe a comparison between arms rather than absolute weight loss.

Where this sits in the pipeline

Ascletis has a U.S. Phase I study already running for ASC36o, the standalone once-weekly oral amylin agonist, with topline human pharmacokinetic data expected by the end of 2026. That readout matters more than the IND: it is the first look at whether any of this holds up outside a primate.

Bottom line

An IND submission is a filing, not an approval, and a once-weekly obesity pill would be genuinely differentiated if the human pharmacokinetics cooperate. Right now the only evidence is animal data generated by the company proposing the trial.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: fda, glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Sermorelin Goes Mainstream on Telehealth, but the Dosing and Efficacy Data Are Missing

Sermorelin, a peptide that stimulates growth-hormone release, is now sold nationally through Hims and Hers as part of its compounded Peptides+ platform. Neither the company nor the outside experts quoted can point to human outcome trials or an established dose.

FDA's Peptide Compounding Shakeup Blurs Drug and Supplement Lines, and Legitimate Brands Are Exposed

New Hope Network reports that FDA's shifting peptide compounding rules have left gray-market injectables like BPC-157 and TB-500 in regulatory limbo, while some supplement brands sell them under a Supplement Facts panel. Industry lawyers call that illegal, and legitimate peptide brands may pay the reputational bill.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.